DK174979B1 - Fast dispersion af FR-900506 samt fremgangsmåder til fremstilling heraf - Google Patents
Fast dispersion af FR-900506 samt fremgangsmåder til fremstilling heraf Download PDFInfo
- Publication number
- DK174979B1 DK174979B1 DK198701404A DK140487A DK174979B1 DK 174979 B1 DK174979 B1 DK 174979B1 DK 198701404 A DK198701404 A DK 198701404A DK 140487 A DK140487 A DK 140487A DK 174979 B1 DK174979 B1 DK 174979B1
- Authority
- DK
- Denmark
- Prior art keywords
- substance
- solid dispersion
- water
- organic solvent
- dispersion composition
- Prior art date
Links
- 239000007962 solid dispersion Substances 0.000 title claims abstract description 32
- 238000000034 method Methods 0.000 title claims abstract description 17
- 238000002360 preparation method Methods 0.000 title claims description 13
- 239000000203 mixture Substances 0.000 claims abstract description 27
- 239000000126 substance Substances 0.000 claims description 53
- 239000000725 suspension Substances 0.000 claims description 17
- 239000003960 organic solvent Substances 0.000 claims description 16
- 229920002678 cellulose Polymers 0.000 claims description 14
- 239000001913 cellulose Substances 0.000 claims description 14
- 229920000642 polymer Polymers 0.000 claims description 13
- 239000000654 additive Substances 0.000 claims description 7
- 239000012456 homogeneous solution Substances 0.000 claims description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 abstract description 2
- CFZGEMKIQUVTCC-UHFFFAOYSA-N octacos-18-ene-2,3,10,16-tetrone Chemical compound CCCCCCCCCC=CCC(=O)CCCCCC(=O)CCCCCCC(=O)C(C)=O CFZGEMKIQUVTCC-UHFFFAOYSA-N 0.000 abstract 1
- 229920003169 water-soluble polymer Polymers 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 33
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 16
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 15
- 238000012360 testing method Methods 0.000 description 11
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 description 10
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 235000010980 cellulose Nutrition 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 7
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 7
- 238000001704 evaporation Methods 0.000 description 7
- 230000008020 evaporation Effects 0.000 description 7
- 239000008101 lactose Substances 0.000 description 7
- 239000000243 solution Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 6
- 239000000741 silica gel Substances 0.000 description 6
- 229910002027 silica gel Inorganic materials 0.000 description 6
- 238000000855 fermentation Methods 0.000 description 5
- 230000004151 fermentation Effects 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- 239000008279 sol Substances 0.000 description 5
- 229920001817 Agar Polymers 0.000 description 4
- 241001647839 Streptomyces tsukubensis Species 0.000 description 4
- 239000008272 agar Substances 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- -1 4-hydroxy-3-methoxycyclohexyl Chemical group 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 229930006000 Sucrose Natural products 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000004744 fabric Substances 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000005720 sucrose Substances 0.000 description 3
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 239000012531 culture fluid Substances 0.000 description 2
- 238000007922 dissolution test Methods 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 238000010828 elution Methods 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 2
- 239000002689 soil Substances 0.000 description 2
- 239000008223 sterile water Substances 0.000 description 2
- 238000010998 test method Methods 0.000 description 2
- 229960000344 thiamine hydrochloride Drugs 0.000 description 2
- 235000019190 thiamine hydrochloride Nutrition 0.000 description 2
- 239000011747 thiamine hydrochloride Substances 0.000 description 2
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 2
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000009329 Graft vs Host Disease Diseases 0.000 description 1
- 239000005909 Kieselgur Substances 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 235000010724 Wisteria floribunda Nutrition 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000016383 Zea mays subsp huehuetenangensis Nutrition 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 239000002518 antifoaming agent Substances 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 239000012225 czapek media Substances 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 238000002329 infrared spectrum Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- 235000009973 maize Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000001103 potassium chloride Substances 0.000 description 1
- 235000011164 potassium chloride Nutrition 0.000 description 1
- 229910000160 potassium phosphate Inorganic materials 0.000 description 1
- 235000011009 potassium phosphates Nutrition 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 235000010344 sodium nitrate Nutrition 0.000 description 1
- 239000004317 sodium nitrate Substances 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000012085 test solution Substances 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D498/18—Bridged systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Transplantation (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Medicinal Preparation (AREA)
- Processes Of Treating Macromolecular Substances (AREA)
- Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
- Reinforced Plastic Materials (AREA)
- Cosmetics (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Colloid Chemistry (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB868608080A GB8608080D0 (en) | 1986-04-02 | 1986-04-02 | Solid dispersion composition |
| GB8608080 | 1986-04-02 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| DK140487D0 DK140487D0 (da) | 1987-03-18 |
| DK140487A DK140487A (da) | 1987-10-03 |
| DK174979B1 true DK174979B1 (da) | 2004-04-05 |
Family
ID=10595572
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK198701404A DK174979B1 (da) | 1986-04-02 | 1987-03-18 | Fast dispersion af FR-900506 samt fremgangsmåder til fremstilling heraf |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US4916138A (cs) |
| EP (1) | EP0240773B1 (cs) |
| JP (1) | JPS62277321A (cs) |
| KR (2) | KR950007209B1 (cs) |
| AT (1) | ATE73327T1 (cs) |
| CA (1) | CA1302279C (cs) |
| DE (1) | DE3777223D1 (cs) |
| DK (1) | DK174979B1 (cs) |
| ES (1) | ES2032397T3 (cs) |
| GB (1) | GB8608080D0 (cs) |
| GR (1) | GR3004124T3 (cs) |
| HK (1) | HK6397A (cs) |
| IE (1) | IE59712B1 (cs) |
| MX (1) | MX9202945A (cs) |
| RU (1) | RU1826977C (cs) |
| UA (1) | UA13209A (cs) |
Families Citing this family (80)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5366971A (en) * | 1987-11-09 | 1994-11-22 | Sandoz Ltd. | Use of 11,28-dioxa-4-azatricyclo[22.3.1.04,9 ]octacos-18-ene derivatives and pharmaceutical compositions containing them |
| JPH02206A (ja) * | 1987-11-11 | 1990-01-05 | Fujisawa Pharmaceut Co Ltd | エキシホンと水溶性高分子化合物とを含有することを特徴とする新規製剤 |
| PH26518A (en) * | 1987-11-11 | 1992-08-07 | Fujisawa Pharmaceutical Co | A novel pharmaceutical composition comprising exifone and water-soluble polymer |
| FR2640137A1 (fr) * | 1988-12-08 | 1990-06-15 | Texinfine Sa | Systemes transporteurs de principes actifs lipophiles et leur procede d'obtention |
| DK0406791T3 (da) * | 1989-07-05 | 1995-03-27 | Fujisawa Pharmaceutical Co | Vandigt flydende præparat til ekstern anvendelse |
| US5208228A (en) * | 1989-11-13 | 1993-05-04 | Merck & Co., Inc. | Aminomacrolides and derivatives having immunosuppressive activity |
| KR0177158B1 (ko) * | 1990-03-01 | 1999-03-20 | 후지사와 도모기찌로 | 면역억제 활성을 갖는 트리사이클릭 화합물 함유 용액 제제 |
| DK0489181T3 (da) * | 1990-07-19 | 1996-11-18 | Otsuka Pharma Co Ltd | Fast præparat |
| US5143918A (en) * | 1990-10-11 | 1992-09-01 | Merck & Co., Inc. | Halomacrolides and derivatives having immunosuppressive activity |
| US5147877A (en) * | 1991-04-18 | 1992-09-15 | Merck & Co. Inc. | Semi-synthetic immunosuppressive macrolides |
| US5565560A (en) * | 1991-05-13 | 1996-10-15 | Merck & Co., Inc. | O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
| US5250678A (en) | 1991-05-13 | 1993-10-05 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynylmacrolides having immunosuppressive activity |
| US5162334A (en) * | 1991-05-13 | 1992-11-10 | Merck & Co., Inc. | Amino O-alkyl, O-alkenyl and O-alkynlmacrolides having immunosuppressive activity |
| US5189042A (en) * | 1991-08-22 | 1993-02-23 | Merck & Co. Inc. | Fluoromacrolides having immunosuppressive activity |
| US5208241A (en) * | 1991-09-09 | 1993-05-04 | Merck & Co., Inc. | N-heteroaryl, n-alkylheteroaryl, n-alkenylheteroaryl and n-alkynylheteroarylmacrolides having immunosuppressive activity |
| ATE183083T1 (de) * | 1992-11-18 | 1999-08-15 | Fujisawa Pharmaceutical Co | Pharmazeutische zubereitung mit verlängerter wirkung |
| DE4316537A1 (de) * | 1993-05-18 | 1994-11-24 | Basf Ag | Zubereitungen in Form fester Lösungen |
| US5693648A (en) * | 1994-09-30 | 1997-12-02 | Merck & Co., Inc. | O-aryl, O-alkyl, O-alkenyl and O-alkynyl-macrolides having immunosuppressive activity |
| FR2736550B1 (fr) * | 1995-07-14 | 1998-07-24 | Sandoz Sa | Composition pharmaceutique sous la forme d'une dispersion solide comprenant un macrolide et un vehicule |
| CA2232378C (en) | 1995-09-19 | 2009-04-14 | Fujisawa Pharmaceutical Co., Ltd. | Aerosol compositions |
| TW426516B (en) * | 1996-12-06 | 2001-03-21 | Fujisawa Pharmaceutical Co | An oral pharmaceutical composition in solid dispersion containing water-insoluble tricyclic compounds |
| BR9809571A (pt) | 1997-04-11 | 2000-07-04 | Fujisawa Pharmaceutical Co | Composição medicinal e processo para produzì-la |
| JP3714970B2 (ja) * | 1998-03-26 | 2005-11-09 | アステラス製薬株式会社 | 徐放性製剤 |
| US6350786B1 (en) * | 1998-09-22 | 2002-02-26 | Hoffmann-La Roche Inc. | Stable complexes of poorly soluble compounds in ionic polymers |
| US6410301B1 (en) | 1998-11-20 | 2002-06-25 | Kosan Biosciences, Inc. | Myxococcus host cells for the production of epothilones |
| AU768220B2 (en) | 1998-11-20 | 2003-12-04 | Kosan Biosciences, Inc. | Recombinant methods and materials for producing epothilone and epothilone derivatives |
| US20050113460A1 (en) * | 1999-04-30 | 2005-05-26 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US7063857B1 (en) | 1999-04-30 | 2006-06-20 | Sucampo Ag | Use of macrolide compounds for the treatment of dry eye |
| ATE433752T1 (de) | 1999-04-30 | 2009-07-15 | Univ Michigan | Verwendung von benzodiazepinen zur behandlung von autoimmunischen krankheiten, entzündungen, neoplasien, viralen infektionen und atherosklerosis |
| US20030119029A1 (en) * | 1999-04-30 | 2003-06-26 | Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and targets thereof |
| US20040176358A1 (en) * | 1999-04-30 | 2004-09-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US20060025388A1 (en) | 1999-04-30 | 2006-02-02 | Glick Gary D | Compositions and methods relating to novel compounds and targets thereof |
| US7144880B2 (en) | 1999-04-30 | 2006-12-05 | Regents Of The University Of Michigan | Compositions relating to novel compounds and targets thereof |
| EP1255763A2 (en) | 2000-02-18 | 2002-11-13 | Kosan Biosciences, Inc. | Motilide compounds |
| US6750047B2 (en) * | 2000-08-21 | 2004-06-15 | Kosan Biosciences, Inc. | Fermentation and purification of migrastatin and analog |
| GB0108498D0 (en) * | 2001-04-04 | 2001-05-23 | Novartis Ag | Organic Compounds |
| WO2003000235A1 (en) * | 2001-06-22 | 2003-01-03 | Pfizer Products Inc. | Pharmaceutical compositions of dispersions of drugs and neutral polymers |
| GB0123400D0 (en) | 2001-09-28 | 2001-11-21 | Novartis Ag | Organic compounds |
| US6989131B2 (en) * | 2002-03-12 | 2006-01-24 | Uop Llc | Catalytic reactor with integral evaporator |
| ES2316805T3 (es) * | 2002-08-29 | 2009-04-16 | Pfizer Inc. | Compuestos motilidos. |
| JP2007527383A (ja) * | 2003-07-09 | 2007-09-27 | チョン クン ダン ファーマスーティカル コーポレイション | タクロリムス固体分散物 |
| JP4903568B2 (ja) * | 2003-08-29 | 2012-03-28 | ベロクシス ファーマシューティカルズ エー／エス | タクロリムスを含む固体分散体 |
| WO2005020993A1 (en) | 2003-08-29 | 2005-03-10 | Lifecycle Pharma A/S | Modified release compositions comprising tacrolimus |
| US20090275099A1 (en) * | 2004-04-27 | 2009-11-05 | Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| US20050272723A1 (en) * | 2004-04-27 | 2005-12-08 | The Regents Of The University Of Michigan | Methods and compositions for treating diseases and conditions associated with mitochondrial function |
| EP1768662A2 (en) | 2004-06-24 | 2007-04-04 | Novartis Vaccines and Diagnostics, Inc. | Small molecule immunopotentiators and assays for their detection |
| US20060014677A1 (en) * | 2004-07-19 | 2006-01-19 | Isotechnika International Inc. | Method for maximizing efficacy and predicting and minimizing toxicity of calcineurin inhibitor compounds |
| US20060052369A1 (en) * | 2004-09-07 | 2006-03-09 | The Regents Of The University Of Michigan | Compositions and methods relating to novel compounds and targets thereof |
| US7638624B2 (en) * | 2005-01-03 | 2009-12-29 | The Regents Of The University Of Michigan | Compositions and methods relating to novel benzodiazepine compounds and derivatives |
| KR100678824B1 (ko) * | 2005-02-04 | 2007-02-05 | 한미약품 주식회사 | 용해성이 증가된 무정형 타크로리무스 고체분산체 및 이를포함하는 약제학적 조성물 |
| CA2611031A1 (en) | 2005-06-01 | 2007-05-10 | The Regents Of The University Of Michigan | Unsolvated benzodiazepine compositions and methods |
| US20070105844A1 (en) * | 2005-10-26 | 2007-05-10 | Regents Of The University Of Michigan | Therapeutic compositions and methods |
| EP1948191B1 (en) | 2005-11-01 | 2013-01-16 | The Regents of the University of Michigan | Novel 1,4-benzodiazepine-2,5-diones with therapeutic properties |
| GB0602632D0 (en) * | 2006-02-08 | 2006-03-22 | Pliva Istrazivacki Inst D O O | Preparation Of A Solid Dosage From Comprising Tacrolimus And/Or Sirolimus |
| US7759338B2 (en) * | 2006-04-27 | 2010-07-20 | The Regents Of The University Of Michigan | Soluble 1,4 benzodiazepine compounds and stable salts thereof |
| JP5264716B2 (ja) | 2006-06-09 | 2013-08-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | 化合物およびその標的に関連する組成物および方法 |
| CA2664641A1 (en) | 2006-09-26 | 2008-04-10 | Astellas Pharma, Inc. | Controlled release dosage form of tacrolimus |
| WO2008084698A1 (ja) | 2006-12-28 | 2008-07-17 | Astellas Pharma Inc. | タクロリムス徐放性医薬組成物 |
| KR101164718B1 (ko) * | 2007-03-09 | 2012-07-11 | 더 리젠츠 오브 더 유니버시티 오브 미시간 | 신규 화합물 및 이의 표적에 관한 조성물 및 방법 |
| US12083103B2 (en) | 2007-05-30 | 2024-09-10 | Veloxis Pharmaceuticals, Inc. | Tacrolimus for improved treatment of transplant patients |
| CA2688381C (en) | 2007-05-30 | 2016-10-11 | Lifecycle Pharma A/S | Once daily oral dosage form comprising tacrolimus |
| AU2008298870C1 (en) | 2007-09-14 | 2014-10-09 | The Regents Of The University Of Michigan | F1F0-ATPase inhibitors and related methods |
| TW200932240A (en) | 2007-10-25 | 2009-08-01 | Astellas Pharma Inc | Pharmaceutical composition containing lipophilic substance which inhibits IL-2 production |
| BRPI0820477A2 (pt) | 2007-11-06 | 2015-06-16 | Univ Michigan | Compostos de benzodiazepinona úteis no tratamento de afecções da pele |
| CL2008000374A1 (es) * | 2008-02-05 | 2008-04-04 | Igloo Zone Chile S A | Composicion farmaceutica que comprende un polvo para suspension oral de tacrolimus o una de sus sales, hidratos o solvatos y excipientes farmaceuticamente aceptables; procedimiento de preparacion de dicha composicion farmaceutica; y uso para la preve |
| KR101003042B1 (ko) | 2008-03-17 | 2010-12-21 | 종근당바이오 주식회사 | 고순도 타크로리무스의 정제 방법 |
| US8222272B2 (en) | 2008-04-11 | 2012-07-17 | Roxane Laboratories, Inc. | Pharmaceutical formulation and process comprising a solid dispersion of macrolide (tacrolimus) |
| US12403095B2 (en) | 2008-05-30 | 2025-09-02 | Veloxis Pharmaceuticals, Inc. | Stabilized tacrolimus composition |
| AU2009291632B2 (en) | 2008-09-11 | 2013-04-04 | The Regents Of The University Of Michigan | Aryl guanidine F1F0-ATPase inhibitors and related methods |
| US8604023B2 (en) | 2009-04-17 | 2013-12-10 | The Regents Of The University Of Michigan | 1,4-benzodiazepinone compounds and their use in treating cancer |
| JP2013505258A (ja) | 2009-09-18 | 2013-02-14 | ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン | ベンゾジアゼピノン化合物およびそれを使用する治療方法 |
| CN102753179A (zh) | 2009-11-17 | 2012-10-24 | 密执安大学评议会 | 具有治疗性能的1,4-苯并二氮杂*-2,5-二酮和相关化合物 |
| CA2780287C (en) | 2009-11-17 | 2015-03-17 | The Regents Of The University Of Michigan | 1,4-benzodiazepine-2,5-diones and related compounds with therapeutic properties |
| PT2575769T (pt) | 2010-02-17 | 2016-09-22 | Veloxis Pharmaceuticals As | Composição de tacrolímus estabilizada |
| WO2011157720A2 (en) | 2010-06-14 | 2011-12-22 | Ratiopharm Gmbh | Ivabradine-containing pharmaceutical composition with modified release |
| MA34586B1 (fr) | 2010-08-25 | 2013-10-02 | Medis Lab | Particules cristallines de tacrolimus micronise a surface modifiee et compositions pharmaceutiques associees |
| KR101243938B1 (ko) * | 2010-10-19 | 2013-03-19 | 이희엽 | 타크롤리무스를 유효성분으로 함유하는 서방형 펠렛 |
| US9757465B2 (en) | 2012-04-11 | 2017-09-12 | Dow Global Technologies Llc | Composition comprising an organic diluent and a cellulose ether |
| US10610491B2 (en) | 2013-09-25 | 2020-04-07 | Dow Global Technologies Llc | Composition comprising an organic liquid diluent and a specific hydroxyalkyl methylcellulose |
| US20170072058A1 (en) | 2014-11-21 | 2017-03-16 | Solipharma Llc | Pharmaceutical composition containing tacrolimus and preparation methods thereof |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL130099C (cs) * | 1963-10-11 | |||
| DE1492034A1 (de) * | 1965-05-18 | 1969-02-20 | Merck Ag E | Verfahren zur Herstellung fester haltbarer Zubereitungen von empfindlichen,in Wasser schwer loeslichen Wirkstoffen,vorzugsweise Arzneimitteln |
| US3852421A (en) * | 1970-03-23 | 1974-12-03 | Shinetsu Chemical Co | Excipient and shaped medicaments prepared therewith |
| GB1322306A (en) * | 1971-04-15 | 1973-07-04 | Meiji Seika Co | Stabilized antibiotic preparation and manufacturing process therefor |
| US4127647A (en) * | 1975-04-08 | 1978-11-28 | Meiji Seika Kaisha, Ltd. | Process for preparation of stable amorphous macrolide antibiotic solids |
| GB1593261A (en) * | 1976-07-23 | 1981-07-15 | Inveresk Res Int | Controlled release suppository |
| GB1579818A (en) * | 1977-06-07 | 1980-11-26 | Yamanouchi Pharma Co Ltd | Nifedipine-containing solid preparation composition |
| DE3013839A1 (de) * | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
| CA1146866A (en) * | 1979-07-05 | 1983-05-24 | Yamanouchi Pharmaceutical Co. Ltd. | Process for the production of sustained release pharmaceutical composition of solid medical material |
| US4259314A (en) * | 1979-12-10 | 1981-03-31 | Hans Lowey | Method and composition for the preparation of controlled long-acting pharmaceuticals |
| US4369172A (en) * | 1981-12-18 | 1983-01-18 | Forest Laboratories Inc. | Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose |
| US4389393A (en) * | 1982-03-26 | 1983-06-21 | Forest Laboratories, Inc. | Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose |
| JPS6038322A (ja) * | 1983-08-11 | 1985-02-27 | Fujisawa Pharmaceut Co Ltd | ジヒドロピリジンａ物質含有易溶性固形製剤 |
| US4894366A (en) * | 1984-12-03 | 1990-01-16 | Fujisawa Pharmaceutical Company, Ltd. | Tricyclo compounds, a process for their production and a pharmaceutical composition containing the same |
-
1986
- 1986-04-02 GB GB868608080A patent/GB8608080D0/en active Pending
-
1987
- 1987-03-14 DE DE8787103716T patent/DE3777223D1/de not_active Expired - Lifetime
- 1987-03-14 AT AT87103716T patent/ATE73327T1/de not_active IP Right Cessation
- 1987-03-14 ES ES198787103716T patent/ES2032397T3/es not_active Expired - Lifetime
- 1987-03-14 EP EP87103716A patent/EP0240773B1/en not_active Expired - Lifetime
- 1987-03-18 DK DK198701404A patent/DK174979B1/da not_active IP Right Cessation
- 1987-03-27 JP JP62075470A patent/JPS62277321A/ja active Granted
- 1987-04-01 KR KR1019870003087A patent/KR950007209B1/ko not_active Expired - Lifetime
- 1987-04-01 IE IE84387A patent/IE59712B1/en not_active IP Right Cessation
- 1987-04-01 RU SU4202275A patent/RU1826977C/ru active
- 1987-04-01 CA CA000533582A patent/CA1302279C/en not_active Expired - Lifetime
- 1987-04-01 UA UA4202275A patent/UA13209A/uk unknown
- 1987-07-01 KR KR1019870007053A patent/KR950007210B1/ko not_active Expired - Lifetime
-
1988
- 1988-07-25 US US07/224,235 patent/US4916138A/en not_active Expired - Lifetime
-
1992
- 1992-03-24 GR GR910402151T patent/GR3004124T3/el unknown
- 1992-06-17 MX MX9202945A patent/MX9202945A/es unknown
-
1997
- 1997-01-16 HK HK6397A patent/HK6397A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| HK6397A (en) | 1997-01-24 |
| GB8608080D0 (en) | 1986-05-08 |
| KR950007210B1 (ko) | 1995-07-04 |
| KR870010073A (ko) | 1987-11-30 |
| MX9202945A (es) | 1992-07-01 |
| EP0240773B1 (en) | 1992-03-11 |
| JPH0536411B2 (cs) | 1993-05-31 |
| EP0240773A1 (en) | 1987-10-14 |
| UA13209A (uk) | 1997-02-28 |
| DK140487D0 (da) | 1987-03-18 |
| US4916138A (en) | 1990-04-10 |
| GR3004124T3 (cs) | 1993-03-31 |
| KR950007209B1 (ko) | 1995-07-04 |
| DE3777223D1 (de) | 1992-04-16 |
| RU1826977C (ru) | 1993-07-07 |
| ES2032397T3 (es) | 1993-02-16 |
| CA1302279C (en) | 1992-06-02 |
| DK140487A (da) | 1987-10-03 |
| IE870843L (en) | 1987-10-02 |
| ATE73327T1 (de) | 1992-03-15 |
| IE59712B1 (en) | 1994-03-23 |
| JPS62277321A (ja) | 1987-12-02 |
| KR890001626A (ko) | 1989-03-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK174979B1 (da) | Fast dispersion af FR-900506 samt fremgangsmåder til fremstilling heraf | |
| KR930010708B1 (ko) | 트리사이클로 화합물의 제조방법 | |
| DK1539977T3 (en) | PREPARATION OF TIACUMICIN | |
| US5091389A (en) | Lipophilic macrolide useful as an immunosuppressant | |
| JP2917305B2 (ja) | Ｆｒ−９０１１５５物質およびその生産法 | |
| JPH078873B2 (ja) | 免疫抑制剤として有効な新規の親油性マクロライド | |
| EP0589703A1 (en) | Proline derivative of rapamycin, production and application thereof | |
| RU2245338C2 (ru) | Способ разделения высокомолекулярных лактонсодержащих соединений | |
| EP1751272A2 (en) | Production of tacrolimus (fk-506) using new streptomyces species | |
| CZ279307B6 (cs) | Rebeccamycinový analog, způsob jeho přípravy a farmaceutický prostředek, který ho obsahuje | |
| CN109988129A (zh) | 化合物及其在制备抗结核药物中的应用 | |
| GB2278844A (en) | Microbial transformation product having immunosuppressive activity | |
| US5359060A (en) | Phosponated derivatives of macrolides | |
| JPH06128282A (ja) | 臭化物前駆物質物質供給によるレベカマイシン類似体 | |
| EP0629209B1 (en) | Sugar derivatives of macrolides | |
| EP0636136B1 (en) | 2-aminosugar derivatives of macrolides | |
| KR930000275B1 (ko) | 항생물질 do-248-a 및 b의 제조방법 | |
| EP0818464B1 (en) | Methylsulfomycin l, a process for its production and its use | |
| WO1992011275A1 (en) | 13-dimethyl fr-900506 derivative and the use as an immunosuppressive agent | |
| SK278338B6 (en) | Rebecamycine analogue, preparation method thereof and pharmaceutical agent containing its |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PUP | Patent expired |